Physician profile
Anthony E Albregts
NPI 1093718751
$845.92
in general payments reported to CMS, 2019-2025
15 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $30.94 · 2022: $23.03 · 2023: $115 · 2024: $333 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $240.82 | 2019-2025 | Skyrizi |
| Genzyme Corporation | $143.00 | 2023-2025 | |
| Strata Skin Sciences, INC. | $89.40 | 2019-2025 | Xtrac |
| Sun Pharmaceutical Industries INC. | $70.36 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $42.81 | 2024-2025 | Dupixent |
| Leo Pharma INC. | $41.26 | 2025 | Anzupgo, Adbry |
| Amgen INC. | $37.45 | 2019-2023 | Otezla |
| Novartis Pharmaceuticals Corporation | $35.89 | 2025 | |
| Organogenesis INC. | $30.94 | 2020 | |
| Blueprint Medicines Corporation | $30.26 | 2023 | |
| Kyowa Kirin, INC. | $23.03 | 2022 | |
| Ucb, INC. | $17.79 | 2025 | Bimzelx |
| Genentech USA, INC. | $15.08 | 2019 | |
| Dermavant Sciences, INC. | $14.36 | 2023 | Vtama |
| Paratek Pharmaceuticals, INC. | $13.47 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Albregts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.